Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) — The “Plantibodies Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering.
The Global Plantibodies Market, valued at USD 60.91 Million in 2024, is projected to experience a CAGR of 8.18% to reach USD 97.63 Million by 2030
Plantibodies are recombinant antibodies produced in genetically modified plants, designed for diverse therapeutic and diagnostic applications.
The market’s growth is predominantly supported by the intrinsic advantages of plant-based expression systems, notably lower production costs, superior scalability compared to conventional mammalian cell cultures, and a mitigated risk of contamination from human or animal pathogens. These systems also offer accelerated production timelines due to the rapid growth characteristics of host plants.
Key Market Drivers
The Global Plantibodies Market is primarily driven by cost-effective production and scalability, along with a significantly reduced risk of pathogen contamination. Plant-based expression systems inherently bypass the high capital investments and operational costs associated with traditional mammalian cell cultures, which demand complex sterile bioreactor environments.
This allows for scalable cultivation in diverse settings, enabling high-volume biopharmaceutical production at lower per-unit expenses. According to the National Science Foundation’s Partnerships for Innovation Research Partnerships (PFI-RP) project, in its 2024 abstract, plant-based biomanufacturing platforms target production exceeding 500 mg per kilogram of plant fresh weight for functional human blood proteins, demonstrating substantial scalability.
Key Market Challenges
The intricate and developing regulatory landscape for plant-derived pharmaceuticals poses a substantial impediment to the growth of the Global Plantibodies Market. The evolving nature of guidelines for genetically modified organisms used in therapeutic production creates uncertainty for developers and investors alike. This complexity often translates into extended timelines for product development and approval, delaying market entry for innovative plantibody candidates.
The compliance burden imposed by diverse and sometimes overlapping regulations significantly increases operational costs for companies engaged in plantibody manufacturing. According to the National Association of Manufacturers, the average manufacturer in the United States incurred over $29,000 per employee per year in federal regulatory compliance costs in 2022, measured in 2023 dollars. This substantial financial overhead, applicable across the manufacturing sector, directly impacts the economic viability of novel plant-based biopharmaceutical ventures.
Key Market Trends
The integration of artificial intelligence into plantibody discovery and optimization is accelerating development timelines and enhancing therapeutic precision. AI algorithms efficiently analyze extensive protein data, predicting optimal modifications for improved binding affinity and efficacy, thereby streamlining initial drug development phases.
According to PhRMA, the biopharmaceutical industry invested nearly $101 billion in research and development in 2022, highlighting the sector’s robust commitment to innovation enabling advanced computational methods. For example, Stanford scientists developed a machine learning method achieving a 25-fold improvement in a SARS-CoV-2 antibody by predicting molecular changes, as reported in Science in July 2024. This showcases AI’s direct influence on identifying highly effective plantibody variants.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $60.91 Million |
| Forecasted Market Value (USD) by 2030 | $97.63 Million |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
Report Scope:
Key Market Players Profiled:
- PlantForm Corporation
- Planet Biotechnology Inc.
- iBio, Inc.
- Mapp Biopharmaceutical, Inc. (Allergan, Inc.)
- Medicago Inc.
- NOMAD Bioscience GmbH
- Ventria Bioscience Inc.
- Agrisera AB
- Creative Biolabs, Inc.
- Protalix BioTherapeutics Inc.
By Transgenic Crop:
- Tobacco
- Legumes
- Cereals
- Seeds & Tubers
- Fruits & Vegetables
- Others
By Technique:
- Conventional Method
- Tissue Culture
- Breeding & Sexual Crossing
- Transgenic Seeds
- Others
By Application:
- Autoimmune Diseases
- Cancer
- Infectious Diseases
- Immunization
- Dentistry
- Others
By End User:
- Biotechnology & Pharmaceutical Companies
- Academic & Research Institutes
- Others
By Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/s3zwy0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
